In an exciting development for Tempus AI (NasdaqGS:TEM), the company experienced a significant 51% increase in its share price over the last quarter. This surge coincides with major events including ...

Tempus AI surges 12.5% on new AI tools, a $200M AstraZeneca deal, and clinical data expansion- but is it time to buy?

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of §§10 ...

Tempus AI Inc. misled investors about the worth of its deals and artificial intelligence abilities, obscuring weaknesses with ...

TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM’s main bet is now on AI for ...

Based on its analysis, Spruce Point stated that Tempus AI stock has the potential to fall about 50% to 60%. From the stock's closing price on Tuesday (the day before Spruce Point released its report), ...

Tempus AI will collaborate with Northwestern University's neurogenomics researchers to use artificial intelligence to accelerate discovery of treatments for Alzheimer's disease, the Chicago-based ...

While large language models have been the primary focus of Wall Street, the real asymmetric returns for savvy growth ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting revenue and backlog. The AI precision medicine company grew core revenues ...